Biotechnology

Ondine Biomedical Inc - Steriwave now available through NHS Supply Chain

June 21, 2024 2:00 AM

Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, is pleased to announce that its Steriwave® nasal photodisinfection is now available through the NHS Supply Chain, making it significantly easier for NHS hospitals in England and Wales to purchase. This marks the first time a light-activated antimicrobial has been available through the NHS Supply Chain, a national body which...

Read more

Luxor Scientific Unveils Cutting-Edge Testing Solutions to Combat Escalating Illicit Drug Crisis

June 20, 2024 2:00 PM

Luxor Scientific, a leader in scientific research, announces groundbreaking advancements in combatting the rise of deadly illicit drugs. Leveraging expertise in toxicology, Luxor has developed advanced testing solutions to address the nation's overdose crises associated with substances like bromazolam, tianeptine, xylazine, and nitazenes, providing healthcare professionals the information needed to develop more effective treatment plans....

Read more

Tharimmune Announces $2.08 Million Private Placement

June 20, 2024 8:00 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, developing lead candidate, TH104 for chronic pruritus in primary biliary cholangitis announced today that it has entered into a securities purchase agreement for the purchase and sale of an aggregate of 659,545 shares of its common stock (or common stock...

Read more

Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

June 20, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / June 20, 2024 / Alligator Bioscience (STO:ATORX) Primary endpoint of OPTIMIZE-1 trial was met, with Objective Response Rate (ORR) of 40.4% in 57 evaluable patients Unprecedented Duration of Response (DoR) and a prolonged Overall Survival (OS) Further validation of data, following recent ASCO presentations and publication in The Lancet Oncology 18-month survival follow-up data from OPTIMIZE-1 expected in late June 2024...

Read more

Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million

June 20, 2024 1:20 AM

Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and...

Read more

Bionoid Pharma Announces Agreement to Acquire AiMaverickIntel.com

June 18, 2024 11:00 AM

Bionoid Pharma, Inc. ("BINP") (OTC Pink:BINP) today announced that it has entered into a Letter of Intent to acquire AiMaverickIntel.com, a leading Audience Acquisition platform powered by Artificial Intelligence (AI). This strategic acquisition underscores BINP's interest in leveraging advanced technology to enhance audience engagement and acquisition strategies. This new agreement follows the cancellation of a previously announced agreement to...

Read more

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

June 18, 2024 9:00 AM

Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research organization ("CRO") to oversee execution of the Company's 12-week chronic study GLP-1-H24-4, (the "Study") which will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar...

Read more

AbTherx Opens Antibody Discovery Technologies Research Center

June 18, 2024 6:00 AM

AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the opening of its new antibody discovery technologies research center. The new state-of-the-art laboratory includes a multimillion-dollar investment in antibody discovery research automation and facilities to develop innovative therapeutics and transgenic mouse technologies. "We are expanding our footprint in San...

Read more

Year-end Report 2023/2024

June 18, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / June 18, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Steadily increasing sales in the USA SEK t Q4 23/24 Q4 22/23 May-April 23/24 May-April 22/23 Net sales 1,899 587 7,290 3,383 Operating profit (loss) -41,490 -37,208 -126,845 -110,457 Earnings per share after dilution -0.47 -0.81 -2.14 -3.18 Number of shares at the end of the period 84,055,560 45,741,450 84,055,560...

Read more

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

June 17, 2024 12:00 PM

IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL. The presentation,...

Read more

Faro Health Inc. Appoints Vivian DeWoskin as Chief Strategy Officer

June 17, 2024 9:00 AM

Vivian joins Faro Health Inc. as the company aims to accelerate the growth and adoption of its market-leading SaaS platform for data-driven clinical development. SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Faro Health Inc., the leading SaaS platform for data-driven clinical development, is pleased to announce the appointment of Vivian DeWoskin as Chief Strategy Officer. Vivian joins the Faro Health team as the company looks to significantly...

Read more

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

June 17, 2024 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports positive Type C meeting feedback from the U.S. Food and Drug Administration (FDA) for its Phase 2 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene for moderate-to-severe pruritus or...

Read more

Hemogenyx Pharmaceuticals PLC Announces Operations Update

June 17, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress. 1. HEMO-CAR-T Clinical Trials Progress: Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the...

Read more

Seraxis Wins Maryland Stem Cell Research Fund Grant to Accelerate Development of Allogenetically Compatible Pancreatic Islet Replacement Therapy for Functional Cure of T1D

June 14, 2024 9:00 AM

$400,000 award will support characterization and efficacy testing of preclinical SR-03 cell line as a part of IND development. Seraxis is taking meetings at the American Diabetes Association Annual Meeting in Orlando, June 21-24. GERMANTOWN, MD / ACCESSWIRE / June 14, 2024 / Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2...

Read more

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

June 14, 2024 8:00 AM

BASEL, SWITZERLAND / ACCESSWIRE / June 14, 2024 / Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, proudly announces the appointment of Virginia Savova, PhD as a strategic and scientific advisor. Scailyte announces Virginia Savova, PhD, as a Strategic and Scientific Advisor Dr. Savova brings strong expertise in computational biology, immunology, and cancer research, with a track record of...

Read more

Elizabeth Fraley, CEO of Kinder Ready, Announces a Customized Summer Learning Program for Early Learners.

June 13, 2024 10:35 PM

In the latest progress, Kinder Ready's CEO, Elizabeth Fraley, launches the Summer Learning Initiative to enhance education skills. The organization's Summer Learning Initiative is aimed at supporting early learners in a variety of areas, including fine motor skills, literacy concepts, guided reading, writing skills, and math concepts. The initiative is led by Elizabeth Fraley, a seasoned Early Childhood Expert and Businesswoman. She focuses on...

Read more

Med-X Announces Registration of the Nature-Cide All-Purpose Commercial Concentrate Product in Mexico

June 13, 2024 3:00 PM

Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced that its Nature-Cide All-Purpose Commercial Concentrate product from its flagship Nature-Cide product division has been successfully registered and approved for use in Mexico, addressing an urgent need for all-natural products that can be safely used in sensitive industries such as agriculture and...

Read more

Renova Therapeutics Announces Potential Expansion of Gene Therapy Platform for Heart Failure, Diabetes and Related Conditions

June 12, 2024 9:00 AM

Renova is exploring new therapeutic opportunities that have the potential to expand the use of Renova's gene therapy platform to include several pathologies associated with diabetes and heart failure. CARLSBAD, CA & SAN DIEGO, CA / ACCESSWIRE / June 12, 2024 / Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today current and potential future clinical...

Read more

Imbiotechnologies Signs Supply Agreement With Medicus Management

June 12, 2024 8:00 AM

IMBiotechnologies Ltd. ("IMBiotechnologies") is pleased to announce the signing of a supply agreement with Medicus Management, LLC ("Medicus"), a group purchasing organization (GPO) currently supplying twenty office-based laboratory (OBL) and ambulatory surgical center (ASC) clinics focused on minimally-invasive procedures. "IMBiotechnologies' Ekobi® microspheres product is truly unique compared to the competitive embolic agents on the market,"...

Read more

GenomesDAO Secures New Investment Round From Pantera Capital and Modular Capital

June 12, 2024 3:00 AM

Biotech company continues to gain momentum in its quest to revolutionize the decentralized genomics market. LONDON, UK / ACCESSWIRE / June 12, 2024 / GenomesDAO, a pioneering biotech company focused on the secure, private, and auditable monetization of genomic data, today announced the successful completion of a new investment round led by Pantera Capital and Modular Capital. Pantera, Modular and GenomesDAO GenomesDAO's flagship product...

Read more